venetoclax combining with fludarabine and melphalan as conditioning regimen prior to allogeneic hematopoietic stem cell transplantation for older patients with hematologic malignancies
It was a phase Ⅱ clinical trial of new designed reduced-intensity conditioning regimen for older patients accepting allogeneic hematopoietic stem cell transplantation treatment. The regimen consisted of venetoclax combining with fludarabine and melphalan.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
50
Venetoclax 400mg/day,oral,day-8~day-2; Fludarabine, 30mg/m2/day,intravenous,d-7~d-3;Melphalan, 140mg/ m2/d,intravenous,day-2
The first Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, China
RECRUITINGFirst Affiliated Hospital of Zhejiang Chinese Medicine University
Hangzhou, Zhejiang, China
RECRUITINGdisease free survival
2-year DFS
Time frame: 2 year
incidence of toxic reaction
2-year incidence of toxic reaction
Time frame: 2 year
overall survival
2-year OS
Time frame: 2 year
cumulative incidence of relapse
2-year incidence of relapse
Time frame: 2 year
incidence of acute and or chronic graft verus host disease
2-year incidence of cGVHD
Time frame: 2 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Second Affiliated Hospital of Zhejiang University, School of Medicine
Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University
Hangzhou, China
RECRUITINGZhejiang Provincial People's Hospital
Hangzhou, China
RECRUITINGNingbo Hospital of Zhejiang University
Ningbo, China
RECRUITINGThe Affiliated People's Hospital of Ningbo University
Ningbo, China
RECRUITINGThe First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China
RECRUITING